Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 10, 2010, Pages 2611-2622

  Bianco Miotto, Tina ^a   Chiam, Karen ^a   Buchanan, Grant ^a,b   Jindal, Shalini ^a   Day, Tanya K ^a   Thomas, Mervyn ^c   Pickering, Marie A ^a   O'Loughlin, Melissa A ^a,b   Ryan, Natalie K ^a   Raymond, Wendy A ^d   Horvath, Lisa G ^e   Kench, James G ^e   Stricker, Phillip D ^e,f   Marshall, Villis R ^g   Sutherland, Robert L ^e,f   Henshall, Susan M ^e,f   Gerald, William L ^h   Scher, Howard I ^h   Risbridger, Gail P ⁱ   Clements, Judith A ^j   Butler, Lisa M ^a   Tilley, Wayne D ^a   Horsfall, David J ^a   Ricciardelli, Carmela ^a,k   more..

^a University of Adelaide   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c Emphron Informatics   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ MONASH UNIVERSITY   (Australia)

^j QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^k UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE H3; HISTONE METHYLTRANSFERASE; KI 67 ANTIGEN;

ACETYLATION; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CARCINOGENESIS; CHEMICAL ANALYSIS; COMPUTER MODEL; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MALE; MICROARRAY ANALYSIS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77958026106     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0555     Document Type: Article

References (57)

1. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007;8:286-98.
2. Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 2007;177:822-31.
3. Hake SB, Xiao A, Allis CD. Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer 2004;90:761-9.
4. Szyf M. DNA methylation and demethylation as targets for anticancer therapy. Biochemistry (Mosc) 2005;70:533-49.
5. Szyf M, Pakneshan P, Rabbani SA. DNA demethylation and cancer: therapeutic implications. Cancer Lett 2004;211:133-43. (Pubitemid 38824627)
6. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-74.
7. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005;45:629-56.
8. Miyamoto K, Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol 2005;35:293-301.
9. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008;15:1968-76.
10. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007;25:4358-64.
11. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
12. Tryndyak VP, Kovalchuk O, Pogribny IP. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther 2006;5:65-70.
13. Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008;40:741-50.
14. Wei Y, Xia W, Zhang Z, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008;47:701-6.
15. Mohamed MA, Greif PA, Diamond J, et al. Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. BJU Int 2007;99:908-15.
16. Yegnasubramanian S, Haffner MC, Zhang Y, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008;68:8954-67.
17. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-6. (Pubitemid 40943093)
18. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705.
19. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
20. Seligson DB, Horvath S, McBrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009;174:1619-28.
21. Henshall SM, Horvath LG, Quinn DI, et al. Zinc-α2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006;98:1420-4.
22. Sakko AJ, Butler MS, Byers S, et al. Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiol Biomarkers Prev 2008;17:2488-97.
23. Horvath LG, Henshall SM, Lee CS, et al. Lower levels of nuclear β-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer 2005;113:415-22.
24. Horsfall DJ, Jarvis LR, Grimbaldeston MA, Tilley WD, Orell SR. Immunocytochemical assay for oestrogen receptor in fine needle aspirates of breast cancer by video image analysis. Br J Cancer 1989;59:129-34.
25. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res 1994;54:4096-102.
26. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Hum Mol Genet 2007;16:R28-49.
27. Hermanek P. [1992 tumor classification/developments]. Langenbecks Arch Chir Suppl Kongressbd 1992:40-5.
28. Elsheikh SE, Green AR, Rakha EA, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009;69:3802-9.
29. Ricciardelli C, Choong CS, Buchanan G, et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 2005;63:19-28.
30. Ricciardelli C, Jackson MW, Choong CS, et al. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate 2008;68:830-8.
31. Buchanan G, Ricciardelli C, Harris JM, et al. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein α. Cancer Res 2007;67:10087-96.
32. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
33. Spin JM, Nallamshetty S, Tabibiazar R, et al. Transcriptional profiling of in vitro smooth muscle cell differentiation identifies specific patterns of gene and pathway activation. Physiol Genomics 2004;19:292-302.
34. Lockwood CA, Ricciardelli C, Raymond WA, Seshadri R, McCaul K, Horsfall DJ. A simple index using video image analysis to predict disease outcome in primary breast cancer. Int J Cancer 1999;84:203-8.
35. Ricciardelli C, Sakko AJ, Stahl J, Tilley WD, Marshall VR, Horsfall DJ. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. Prostate 2009;69:761-9.
36. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
37. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007;67:547-56.
38. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003;95:661-8.
39. Patra SK, Patra A, Zhao H, Dahiya R. DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog 2002;33:163-71.
40. Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 2007;6:1403-12.
41. Pritchard C, Mecham B, Dumpit R, et al. Conserved gene expression programs integrate mammalian prostate development and tumorigenesis. Cancer Res 2009;69:1739-47.
42. Comuzzi B, Nemes C, Schmidt S, et al. The androgen receptor coactivator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 2004;204:159-66.
43. Hong H, Kao C, Jeng MH, et al. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 2004;101:83-9.
44. Isharwal S, Miller MC, Marlow C, Makarov DV, Partin AW, Veltri RW. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate 2008;68:1097-104.
45. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63:7638-40.
46. Fu M, Rao M, Wang C, et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 2003;23:8563-75.
47. Fu M, Wang C, Reutens AT, et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 2000;275:20853-60. (Pubitemid 30457679)
48. Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 2001;287:705-13.
49. Halkidou K, Cook S, Leung HY, Neal DE, Robson CN. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol 2004;45:382-9, author reply 9.
50. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59:177-89.
51. Weichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98:604-10.
52. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
53. Tzao C, Tung HJ, Jin JS, et al. Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol 2009;22:252-60.
54. Ellinger J, Kahl P, von der Gathen J, et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010;70:61-9.
55. Ke XS, Qu Y, Rostad K, et al. Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One 2009;4:e4687.
56. Ozdag H, Teschendorff AE, Ahmed AA, et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006;7:90.
57. Pang ST, Weng WH, Flores-Morales A, et al. Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer. Prostate 2006;66:157-72.